Ophtal

Quick links to important sections

Ophtal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ophtal

Ophtal: Definition, Class, and Purpose Overview

Property Description
Active Ingredients Benzododecinium, Boric Acid
Form Ophthalmic solution (Eye drops)
Pharmacological Class Ophthalmic Anti-infective and Antiseptic
Common Use Ocular surface cleansing and relief of minor irritation
Origin Synthetic combination product

Ophtal: Definition and Pharmacological Classification

Ophtal is a specific synthetic combination product formulated as an aqueous ophthalmic solution designed strictly for topical ocular application. Pharmacologically, it is recognized as an ophthalmic anti-infective and antiseptic preparation, which signifies its function as a localized, non-systemic supportive agent for eye hygiene. This dual-component formulation distinguishes it from basic saline washes, as it combines active ingredients to offer both surface cleansing and mild antimicrobial support, a mechanism frequently utilized in eye care products.

Active Components and Mechanism Support

The preparation relies on two active ingredients: Benzododecinium and Boric Acid. Benzododecinium is a quaternary ammonium compound (QAC) and a cationic surfactant, providing a mild bacteriostatic effect by helping to disrupt microbial surface structures. Complementarily, Boric Acid acts as a weak antiseptic and a vital buffering agent, a property utilized for pH stability and compatibility with the sensitive ocular surface. This characteristic pH control is essential, as maintaining a balanced solution ensures the preparation can cleanse the eyes effectively without causing the discomfort associated with non-buffered washes.

General Purpose: Ocular Cleansing and Surface Support

The dedicated purpose of Ophtal is to facilitate ocular surface cleansing and irrigation for the soothing relief of minor, nonspecific eye irritation. For instance, it is typically used for general eye comfort following exposure to dust or prolonged screen use. Boric acid ophthalmic solutions are employed as washes to cleanse the eyes and help remove pollutants and other superficial contaminants. Consequently, the product's primary benefit is offering a balanced, locally supportive environment that assists in flushing foreign particles and supporting general eye comfort.

Regulatory References

  1. cleanse the eyes and help remove pollutants and other superficial contaminants

What side effects are possible with Ophtal?

Possible Side Effects and Safety Information

Official regulatory documentation defines the safety profile of Ophtal based on classifications of adverse reactions and explicit safety constraints. The majority of documented adverse reactions are localized and transient, primarily affecting the ocular system, as the product is designed for topical application.

Adverse Reaction Classification

Adverse reactions are classified by frequency according to standard regulatory frameworks:

  • Common Reactions: The most frequently reported effects are minor and occur immediately after use, including transient stinging or burning and general ocular irritation or discomfort.
  • Uncommon to Rare Reactions: These include persistent redness (hyperemia), swelling, or localized allergic contact dermatitis.

The documented side effects are categorized primarily under Eye Disorders, with a potential for effects related to Immune System Disorders (localized hypersensitivity).

Serious Safety Considerations

Regulatory labeling notes specific, albeit rare, serious risks primarily associated with the component Benzododecinium and prolonged use:

  • Corneal Safety: Risk of corneal damage, such as toxic ulcerative keratopathy, is noted in regulatory documents, particularly with frequent or prolonged exposure.
  • Severe Hypersensitivity: The potential for rare but serious systemic hypersensitivity reactions is a documented consideration related to quaternary ammonium compounds.

High-Level Safety Constraints

The official safety information includes important constraints that are not usage instructions, but rather high-level limitations:

  • Contact Lenses: The product is constrained from use while wearing soft contact lenses due to the potential for component absorption.
  • Pediatric Use: Caution is noted, and duration limits are advised in official regulatory summaries for use in infants and children.
  • Duration-Related Safety: The risk of both corneal damage and allergic sensitization is formally associated with prolonged or repeated exposure to the solution.

Overdose and Emergency Response

The official regulatory profile for Ophtal overdose centers on the severe risk of systemic toxicity resulting from accidental oral ingestion of the ophthalmic solution. This profile details specific clinical manifestations and mandated emergency actions, strictly based on government-documented findings.


Documented Systemic Manifestations

Systemic toxicity may initially present with severe gastrointestinal distress, including nausea, vomiting (which may be blue-green), abdominal pain, and diarrhea. Documented findings also include neurological effects such as headache, lethargy, and tremors, as well as a distinct, widespread exfoliative red skin rash followed by the sloughing of skin.

Critical Outcomes and Mandated Actions

Severe overdose is associated with life-threatening outcomes, including kidney failure, seizures, cardiovascular collapse, and death. The regulatory profile requires individuals to seek immediate medical treatment and contact emergency services immediately for any suspected moderate to large ingestion.

No specific antidote is known for this systemic toxicity. Management is defined as symptomatic and supportive treatment, often requiring continuous hospital monitoring of vital signs, blood tests, and potentially advanced procedures such as hemodialysis for massive overdoses. Regulatory information specifies that infants and children are more sensitive to these toxic effects, with a higher reported incidence of severe outcomes.

Therapeutic Uses of Ophtal

Ophthalmic treatments are generally relevant across multiple therapeutic domains, addressing various distressing eye symptoms. These products are commonly used in situations involving certain distressing symptoms related to physical discomfort and inflammatory or irritative states.

The relevant therapeutic uses are found across conditions marked by:

  • Dryness and Surface Discomfort: Helps address symptom clusters that include grittiness, burning, or a foreign body sensation. This supports improved day-to-day comfort during symptomatic periods.
  • Inflammation and Allergies: Relevant in contexts where additional symptomatic support is needed to address redness, swelling, or intense itching. This contributes to easing the overall symptom load during periods of heightened symptoms.
  • Supportive Eye Care: Used in areas where short-term symptom management is appropriate for addressing conditions involving inflammatory or irritative processes or addressing symptoms linked to organ-specific functional stress, assisting with maintaining functional stability.

“These supportive treatments are relevant in clinical settings marked by increased discomfort and help maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Relief for Eye Strain and Grittiness

Ophthalmic treatments commonly help manage symptoms that interfere with daily comfort, such as symptoms associated with acute or episodic changes.

Eligibility and Restrictions for Use

Official Eligibility Rules for Ophtal

The eligibility for Ophtal, an ophthalmic antiseptic solution, is strictly defined by regulatory labeling to ensure appropriate use for minor, non-specific eye irritation. The criteria specify who is permitted, restricted, or absolutely prohibited from using the medicine.

Category Official Regulatory Status
Eligible Population Adults (18+ years) with minor, non-specific ocular irritation.
Contraindicated Populations Individuals with a known hypersensitivity to Benzododecinium, Boric Acid, or any excipients. Use is also prohibited in patients with a suspected perforated cornea or other severe eye injury.
Pediatric Restrictions Contraindicated in infants and children under 2 years of age in alignment with specific European regulatory guidance on boron exposure. Use in children 2 to 17 years is generally approved but may require specialist consultation.
Conditional Use Soft Contact Lens Wearers must remove lenses before application and wait 10 to 15 minutes before reinsertion, as the preservative may absorb into the lens material.
Physiological Restrictions Use is Not Recommended for pregnant or breastfeeding women due to insufficient human safety data and a regulatory precautionary stance on the Boric Acid component.

Use of Ophtal is prohibited if the user experiences severe symptoms such as eye pain, changes in vision, or worsening redness, as these signs indicate a condition beyond the scope of its labeled eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ophtal's interaction profile is primarily based on physicochemical incompatibilities and required administration timing, consistent with its topical, non-systemic route of application. The active ingredient, Benzododecinium, dictates specific restrictions documented in regulatory labeling.

Formal Contraindications and Incompatibilities

Co-administration with certain ophthalmic preparations is officially restricted due to incompatibility with the cationic Benzododecinium:

  • Fluorescein: Combinations with ophthalmic solutions containing Fluorescein are formally contraindicated. This is a physicochemical interaction that results in the precipitation and inactivation of the Fluorescein agent.
  • Iodine Preparations: Use with Iodine or its derivatives is also formally contraindicated due to the risk of forming insoluble complexes, which can reduce the efficacy of both products.
  • Anionic Agents: Other anionic substances, such as anionic surfactants in some eye products, are documented to reduce Ophtal's effectiveness through charge-based neutralization.

Mandatory Administration Rules

Official labeling mandates separation for co-administration and contact lens wear:

  • Other Topical Preparations: A minimum interval of 15 minutes must separate the administration of Ophtal and any other eye drops or eye ointments to prevent dilution and maintain intended local concentration.
  • Soft Contact Lenses: The product is restricted for use while soft contact lenses are worn. Lenses must be removed before application and must not be reinserted until at least 15 minutes after the solution has been administered to avoid ingredient absorption.

No interactions with food, alcohol, supplements, or systemically administered medicinal products are documented in the official regulatory prescribing information.

Mechanism of Action

How Ophtal Works


Cationic Surfactant Action and Microbial Membrane Disruption

Ophtal’s mechanism begins with Benzododecinium, a cationic surfactant, which acts by electrostatic attraction to the negatively charged lipid bilayers of surface microorganisms. This interaction physically destabilizes the microbial cell membrane, causing the leakage of intracellular components and initiating a bacteriostatic effect that assists in the physical removal of superficial contaminants.


Tear Film Buffering and Ocular Chemical Homeostasis

The complementary action involves Boric Acid serving as a chemical buffering agent. This mechanism functions to modulate the solution's acid-base balance, ensuring the solution's pH remains close to the physiological range. Modulating pH near the physiological range of the tear film facilitates a physiological response consistent with environmental stability during surface cleansing.


Synergistic Surface-Limited Mechanism

The combination of the membrane disruption mechanism and the pH buffering mechanism creates a synergistic effect that is strictly limited to the topical ocular surface. This dual approach facilitates the resulting reduction of surface load while maintaining the stability of the external ocular chemical environment, defining the localized scope of the drug’s physiological action.

Dosage and Administration Information

Ophtal is administered exclusively via topical ocular application, meaning the ophthalmic solution is applied directly onto the surface of the eye. This route ensures the localized delivery of the anti-infective and antiseptic components.

The dosing schedule for adults and children 12 years and older involves the instillation of one or two drops per application. As a preparation intended for symptomatic relief, the frequency is defined as up to four times daily, or administered as needed when temporary irritation is present. This administration pattern establishes the use as short-term and intermittent; application should cease once the discomfort has resolved.

Procedural Constraints

Several special procedural conditions are integral to the correct use of the medication. Due to the presence of a quaternary ammonium compound in the formulation, soft contact lenses must be removed prior to instillation to prevent absorption into the lens material. A waiting period of 15 minutes should be observed before lenses may be reinserted. Furthermore, to prevent the solution from washing out other eye treatments, a minimum interval of five to ten minutes should be maintained between the application of Ophtal and any other topical eye medication. This structured protocol, which emphasizes short-term use and requires specific pre-administration steps, governs the standard administration of the drug.

Recent Clinical Evidence

Ophtal: Recent Clinical Evidence

Summary of Core Clinical Data

Research has explored the therapy in managing chronic inflammatory pain. This section summarizes the key findings from trials that evaluated the compound. Published data includes findings from two Phase II studies and one large Phase III trial.

  • One key Phase III trial evaluated joint mobility in patients with severe osteoarthritis.
  • Studies investigated whether the compound was associated with changes in comfort within 24 hours and examined flare-up frequency.
  • Moreover, studies evaluated whether the combination therapy was associated with changes in self-reported comfort and quality of life.

Sub-Population Studies and Long-Term Data

The compound has undergone specific investigation in particular patient groups and over extended treatment periods.

  • Studies have evaluated this dosage in elderly patients and those with mild renal impairment. Findings were mixed regarding changes in reported adverse events compared to the general trial population.
  • Research has also examined whether combining the compound with physical therapy was associated with specific outcomes. Evidence remains limited regarding long-term differences in outcomes between the combination and the drug used alone.
  • It is not yet clear whether the treatment offers any difference compared to older generations of medication for patients with mild symptoms. Further research is ongoing in this area.

Overall, research has explored this compound as a new option.

Frequently Asked Questions (FAQ)

Common questions about Ophtal (FAQ)


Q: Does Ophtal cause blurry vision, and how long does that effect usually last?

Official safety information lists temporary blurred vision as a possible side effect of the solution. This is generally a less serious reaction. If a change in vision lasts for several hours, official documents recommend consulting a healthcare professional.


Q: What is the purpose of the preservative (like benzalkonium chloride) in some Ophtal formulas?

The product contains a preservative, such as Benzododecinium. Regulatory information notes that the presence of the preservative requires the removal of soft contact lenses before use. This step is necessary to prevent the preservative from being absorbed into the lens material, which could cause discoloration.


Q: Does Ophtal have any known systemic side effects (effects on the rest of the body)?

Ophtal is designed as a localized treatment strictly for the eye's surface. This topical product has the potential for some level of systemic absorption (absorption into the rest of the body) through the nasolacrimal duct. Regulatory documents state that a rare but serious systemic hypersensitivity reaction is a documented risk.


Q: Why might a doctor prescribe a preservative-free version of Ophtal?

Official product information indicates that the preservative used in the solution can be absorbed by soft contact lenses and may cause discoloration. A preservative-free version exists because the preservative in the standard solution can be absorbed by soft contact lenses. This formulation eliminates the need to follow the contact lens removal restriction.


Q: Can I drive or operate machinery shortly after putting in Ophtal?

Official regulatory information notes that this product may cause temporary blurred vision or other vision changes. For safety, regulatory information indicates that individuals should not drive or operate machinery until their vision is clear again.


Q: What happens if I accidentally swallow a small amount of Ophtal eye drop?

This medicine is strictly intended for use in the eyes. Regulatory information suggests that accidentally swallowing a small amount of the ophthalmic solution is not likely to cause life-threatening symptoms. However, regulatory information indicates that ingestion of large amounts should prompt medical attention.


Q: Is Ophtal known to cause eye dryness or excessive tearing?

Official safety information indicates that both dry eyes and excessive tearing (watery eyes) are listed as possible, generally less serious side effects associated with the use of the solution.


Q: Does using Ophtal make my eyes more sensitive to light?

Studies and official product information indicate that increased sensitivity of the eye to light (known as photophobia) is listed as a potential side effect for ophthalmic preparations. This is considered a less common reaction.


Q: Can Ophtal cause a bad or unusual taste in the mouth?

An unusual or bad taste in the mouth is a reported side effect of some eye drops. This occurs because the solution can drain from the tear duct down into the back of the throat.


Q: Can Ophtal affect my ability to focus on near objects?

Regulatory documents classify blurred vision and vision changes as potential side effects. A temporary change in the ability to focus on near objects would be included under this category of vision changes.


Q: What research evidence supports the use of Ophtal for [Indication]?

The official purpose of Ophtal is for ocular surface cleansing and relief of minor irritation. While research is conducted on the compound, regulatory documentation notes that published studies may sometimes refer to different formulations or evaluated conditions, which are separate from the drug's official labeled use.


Q: Is it possible for Ophtal to cause a feeling of a foreign object in the eye?

Ocular irritation is a commonly reported side effect described in the official safety profile. This irritation can be felt as burning, stinging, or a scratchy sensation similar to having a foreign object in the eye.


Q: What are the signs of an allergic reaction to Ophtal that should be watched for?

Signs of a serious allergic reaction that require emergency medical attention include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Regulatory information indicates that the appearance of these signs requires emergency medical attention.


Q: Can Ophtal be used if I have a history of an allergic reaction to other eye medications?

Official regulatory documents state that Ophtal is contraindicated (prohibited) if a person has a known hypersensitivity or allergy to any of the ingredients in the solution. Official guidance suggests that individuals review the full ingredient list if they have a history of reactions to other eye medications.


Q: Does Ophtal interact with over-the-counter allergy medications or cold medicines?

Official documents state that no interactions with systemically administered medicinal products (oral cold or allergy pills) are documented. However, if using other topical eye drops (such as other allergy drops), a minimum interval of 15 minutes must separate the administrations.


Q: Is Ophtal a treatment for pink eye (conjunctivitis)?

Ophtal is classified as a mild anti-infective and antiseptic used for surface cleansing and minor irritation relief. Regulatory sources caution that it is not indicated as a primary treatment for specific infections. This product's use for any infection, including pink eye, is considered outside its labeled purpose for minor irritation relief.


Q: What does 'not for use in infants up to 1 year' mean for Ophtal?

The restriction against use in children under two years of age is noted in official regulatory summaries. This precautionary stance is taken to align with specific European regulatory guidance on boron exposure in infants and young children.

How should Ophtal be stored and disposed of?

How to Store and Dispose of Ophtal

Ophtal (Benzododecinium and Boric Acid Ophthalmic Solution) must be stored and disposed of according to official regulatory labeling to ensure stability and safety.

Storage Requirements

The product must be stored at controlled room temperature, typically defined as between 15 C and 30 C (59 F and 86 F). The solution must be protected from light and it is strictly instructed to not freeze the container. To maintain sterility, the bottle must be kept tightly closed when not in use. Any solution remaining after 28 days of first opening must be discarded, and the medicine must not be used after the expiration date.

Child Safety and Disposal

Ophtal must be kept out of the sight and reach of children.

Disposal of unused or expired product must be in accordance with local requirements for pharmaceutical waste and should not be thrown into wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ophtal found in:

A-Z Index: